Palantir's High-Flying Valuation Meets a Triple Threat

Palantir's high valuation is tested by competition from Anthropic, shifting geopolitics, and regulatory scrutiny in Europe, despite robust Q4 2025 results.

Palantir Technologies Inc. finds its stock under unusual pressure, even as the broader tech sector rallies. The data analytics firm, long a darling of investors betting on government contracts and artificial intelligence, is navigating a confluence of challenges that have exposed the fragility of its sky-high valuation. While its operational performance remains robust, a mix of rising competition, shifting geopolitical winds, and regulatory scrutiny is testing investor conviction.

The stock closed Wednesday's session at 133.38 euros, extending its year-to-date decline to nearly seven percent. This drop came despite a strong fourth-quarter 2025 report, where revenue surged 70 percent to $1.41 billion and GAAP net income reached $609 million. The core issue isn't current performance; it's the premium price attached to it. With a price-to-earnings ratio hovering around 261 and a price-to-sales multiple of 80, the market is pricing in near-perfect execution and leaves no room for doubt.

A significant new source of that doubt is emerging competition. Famed investor Michael Burry, who holds a short position in Palantir, has publicly targeted the company, arguing it is being displaced in the enterprise market by AI rival Anthropic. He points to Anthropic's explosive growth, with its annualized revenue rate reportedly skyrocketing from $9 billion to $30 billion in just a few months—a scale Palantir took two decades to approach. Data from financial platform Ramp suggests Anthropic captured roughly 73 percent of all new enterprise AI spending in early 2026, a claim that underscores the threat of simpler, more cost-effective alternatives to Palantir's premium offerings.

Geopolitical trends are also turning from a tailwind into a headwind. Recent de-escalation in the Middle East, including an announced two-week ceasefire between the U.S. and Iran and the reopening of the Strait of Hormuz, has reduced market anxiety. This has eroded the "war premium" that previously benefited defense-heavy stocks like Palantir, even as the Nasdaq-100 gained on the reduced risk.

Across the Atlantic, regulatory and political hurdles are mounting. In the UK, Palantir faces growing skepticism despite securing a recent test contract with the Financial Conduct Authority (FCA) to combat financial crime. The company's controversial £330 million deal with the National Health Service (NHS) remains a flashpoint, with politicians increasingly calling for its termination and citing concerns over the firm's foreign security ties. These controversies are seen as potentially limiting future contract growth in sensitive European markets.

Internally, signals have been mixed. While the company boasts a fortress balance sheet with $7.2 billion in cash and no debt, its international commercial business grew a mere 2.5 percent in fiscal 2025. Recent insider sales have also drawn attention, with co-founder Peter Thiel selling shares worth over $290 million, though these were executed under a pre-arranged trading plan.

Leadership remains outwardly confident. CEO Alex Karp is targeting at least $3.14 billion in revenue for the U.S. commercial segment in 2026, a 115 percent year-over-year increase. His long-term ambition is to reach $45 billion in total revenue by the early 2030s. Analyst opinions, however, reflect the current divide. While the consensus price target sits at $197.77, Benchmark recently initiated coverage with a more cautious $150 target and a "Hold" rating. The gap between these assessments highlights the uncertainty over whether Palantir can justify its immense valuation by translating its operational strength into sustained growth beyond its core government business.